www.StockMarketFunding.com Human Genome’s ‘Blockbuster’ Drug Benlystal Potential Undervalued in Bid by GSK vs HGSI BREAKING NEWS! Human Genome Rejects $2.6B Bid From GlaxoSmithKline (Update 1). The stock is currently trading at $14.50 up over 100% on a “MASSIVE SHORT SQUEEZE”! (SMF is long several long term calls on HGSI) Pre-Market Volume Alert! HGSI Buyout by GSK Rejected shares up 100%. Massive Short Squeeze Alert was given on HGSI on 1 www.youtube.com Human Genome Sciences closed near $7 yesterday, but GlaxoSmithKline stunned investors with a $13-per share takeover offer! HGSI is doubling in the premarket, and is well above that bid price. Shares of Human Genome (HGSI) are rallying 109% in pre-market trading to $15.00 after the company disclosed that GlaxoSmithKline (GSK) made a $13.00 per share offer to acquire the company. Human Genone said the offer “does not reflect the value inherent in HGS” and hired Goldman Sachs as well as Credit Suisse to explore of strategic alternatives, including a potential sale.
